| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.081 | 0.03 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.03 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.04 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.073 | 0.04 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.04 |